Is Biohaven (BHVN) Priced At A Premium After Its 36% Rise?

Biohaven has climbed 35.8% year to date, yet its low value score and pricing on the richer side of market multiples raise questions about how much upside is already in the share price.

• The 35.8% year to date gain signals investors have been willing to pay up for Biohaven, which can leave less room for disappointment if sentiment cools.
• The recent licensing deal with SK Biopharmaceuticals for epilepsy candidate opakalim may support long term pipeline value, while handing development and commercialization to a partner can also concentrate execution risk on fewer in house programs.
• With a value score of 2 out of 6, Biohaven currently screens as expensive rather than a clear bargain on broader valuation checks.

The issue now is whether Biohaven's current market price already reflects the upside from its partnerships and drug portfolio or still leaves a reasonable margin for new buyers.

Balance that 35.8% year to date move in Biohaven by scanning for other high quality companies that still appear reasonably priced using 49 high quality undervalued stocks

Is Biohaven Getting Expensive on Book Value?

P/B is usually a better fit for Biohaven because the business is still loss making, so earnings-based metrics like P/E do not anchor the valuation well. On this yardstick, the picture is stark. Biohaven trades on a P/B of about 181.9x, while the wider biotech industry sits closer to 2.5x and peers average roughly 12.2x. That is a very large premium to both the sector and similar companies.

The gap suggests the market is assigning substantial value to Biohaven’s pipeline and future prospects relative to its current equity base. The recent opakalim licensing deal with SK Biopharmaceuticals may help explain some of the enthusiasm, because it puts a concrete spotlight on one asset in the portfolio, yet the P/B level still prices the shares at a steep valuation versus typical biotech benchmarks.

On the price-to-book lens, Biohaven appears overvalued compared with both the biotech industry and peer companies.

See what the numbers say about this price — find out in our valuation breakdown.

The Biohaven Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Biohaven's valuation puzzle leaves off by spelling out which expectations on future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's market price. Each narrative treats fair value as a hypothesis about Biohaven's business that you can track over time rather than a one off snapshot, all housed on the company's Community page.

Add your voice to the Simply Wall St community by setting out a clear, number driven narrative on Biohaven that others can test as fresh data comes through. If you have a view on whether the opakalim deal with SK Biopharmaceuticals ultimately delivers on its potential, this is your chance to put that thesis on the record and watch how it plays out.

Do you think there's more to the story for Biohaven? Head over to our Community to see what others are saying!

The Bottom Line

Biohaven screens as overvalued on traditional market multiples, with an extreme gap between its P/B ratio and typical biotech benchmarks, and broader checks lining up with that message rather than contradicting it. That kind of premium usually means sentiment and expectations are carrying more weight than the current balance sheet. For anyone considering the shares today, the real hinge issue is whether the existing pipeline and partnership agreements ultimately grow into that rich valuation or whether the market eventually reins in the multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com